Antivascular Endothelial Growth Factor Agents Pretreatment Before Vitrectomy for Complicated Proliferative Diabetic Retinopathy: a Meta-analysis of Randomised Controlled Trials

Overview

Journal Br J Ophthalmol

Specialty Ophthalmology

Date 2017 Dec 17

PMID 29246890

Citations 33

Authors

Xin-Yu Zhao

Song Xia

You-Xin Chen

Affiliations

Soon will be listed here.

Abstract

Background/aims: To evaluate the efficacy of antivascular endothelial growth factor (anti-VEGF) agents pretreatment before vitrectomy for patients with complicated proliferative diabetic retinopathy (PDR).

Methods: The PubMed, Embase and the Cochrane Central Register of Controlled Trials were searched up to June 2017 to identify related studies. The Peferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines were followed. The StataSE V.12.0 software was used to analyse the relevant data. The weighted mean difference, relative risk and their 95% CIs were used to assess the strength of the association.

Results: 14 randomised controlled trials involving 613 patients were assessed, the anti-VEGF pretreatment group included 289 patients and the control group included 324 patients. Our analysis indicated that anti-VEGF pretreatment before vitrectomy for complicated PDR could facilitate much easier surgery regarding less intraoperative bleeding, less endodiathermy, shorter duration of surgery, less iatrogenic retinal breaks, less frequency of using silicone oil and relaxing retinotomy (P<0.05). Additionally, anti-VEGF pretreatment could also achieve better postoperative best-corrected visual acuity, less early recurrent vitreous haemorrhage (VH) and quicker absorption of recurrent VH (P<0.05). However, the incidence of late recurrent VH, recurrent retinal detachment or related secondary surgery could not be reduced (P>0.05).

Conclusion: The pretreatment of anti-VEGF agents before vitrectomy for patients with complicated PDR might facilitate much easier surgery and better visual rehabilitation, reduce the rate of early recurrent VH and accelerate its absorption. Moreover, future better-designed studies with larger sample sizes are required to further evaluate the efficacy of different anti-VEGF agents and reach a firmer conclusion.

Citing Articles

Preoperative Intravitreal Conbercept Injection Reduced Both Angiogenic and Inflammatory Cytokines in Patients With Proliferative Diabetic Retinopathy.

Huang Z, Chen L, Huang D, Yi J, Chen Z, Lin P J Diabetes Res. 2024; 2024:2550367.

PMID: 39308630 PMC: 11416173. DOI: 10.1155/2024/2550367.

Personalized Management of Patients with Proliferative Diabetic Vitreoretinopathy.

Ecsedy M, Szabo D, Szilagyi Z, Nagy Z, Recsan Z Life (Basel). 2024; 14(8).

PMID: 39202734 PMC: 11355517. DOI: 10.3390/life14080993.

Recent advances in the treatment and delivery system of diabetic retinopathy.

Wang Z, Zhang N, Lin P, Xing Y, Yang N Front Endocrinol (Lausanne). 2024; 15:1347864.

PMID: 38425757 PMC: 10902204. DOI: 10.3389/fendo.2024.1347864.

Analysis of Risk Factors for Revitrectomy in Eyes with Diabetic Vitreous Hemorrhage.

Guo H, Li W, Wang K, Nie Z, Zhang X, Bai S Diabetes Metab Syndr Obes. 2023; 16:2865-2874.

PMID: 37753483 PMC: 10518247. DOI: 10.2147/DMSO.S429938.

Combined Use of Anti-VEGF Drugs Before and During Pars Plana Vitrectomy for Severe Proliferative Diabetic Retinopathy.

Sun X, Wang X, Guo X, Wang M, Liu H Ophthalmol Ther. 2023; 12(6):3133-3142.

PMID: 37713065 PMC: 10640465. DOI: 10.1007/s40123-023-00803-z.

References

Su L, Ren X, Wei H, Zhao L, Zhang X, Liu J . INTRAVITREAL CONBERCEPT (KH902) FOR SURGICAL TREATMENT OF SEVERE PROLIFERATIVE DIABETIC RETINOPATHY. Retina. 2015; 36(5):938-43. DOI: 10.1097/IAE.0000000000000900. View

Ahmadieh H, Shoeibi N, Entezari M, Monshizadeh R . Intravitreal bevacizumab for prevention of early postvitrectomy hemorrhage in diabetic patients: a randomized clinical trial. Ophthalmology. 2009; 116(10):1943-8. DOI: 10.1016/j.ophtha.2009.07.001. View

Furlan A, Pennick V, Bombardier C, van Tulder M . 2009 updated method guidelines for systematic reviews in the Cochrane Back Review Group. Spine (Phila Pa 1976). 2009; 34(18):1929-41. DOI: 10.1097/BRS.0b013e3181b1c99f. View

Blankenship G, MACHEMER R . Long-term diabetic vitrectomy results. Report of 10 year follow-up. Ophthalmology. 1985; 92(4):503-6. DOI: 10.1016/s0161-6420(85)34015-0. View

Xie X, Xu L, Jonas J, Wang Y . Prevalence of diabetic retinopathy among subjects with known diabetes in China: the Beijing Eye Study. Eur J Ophthalmol. 2009; 19(1):91-9. DOI: 10.1177/112067210901900114. View

Morera Y, Gonzalez R, Lamdan H, Perez L, Gonzalez Y, Aguero J . Vaccination with a mutated variant of human Vascular Endothelial Growth Factor (VEGF) blocks VEGF-induced retinal neovascularization in a rabbit experimental model. Exp Eye Res. 2014; 122:102-9. DOI: 10.1016/j.exer.2014.03.006. View

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009; 62(10):1006-12. DOI: 10.1016/j.jclinepi.2009.06.005. View

El-Batarny A . Intravitreal bevacizumab as an adjunctive therapy before diabetic vitrectomy. Clin Ophthalmol. 2009; 2(4):709-16. PMC: 2699790. View

van Geest R, Lesnik-Oberstein S, Tan H, Mura M, Goldschmeding R, van Noorden C . A shift in the balance of vascular endothelial growth factor and connective tissue growth factor by bevacizumab causes the angiofibrotic switch in proliferative diabetic retinopathy. Br J Ophthalmol. 2012; 96(4):587-90. PMC: 3308470. DOI: 10.1136/bjophthalmol-2011-301005. View

10.

Schachat A, Oyakawa R, Michels R, Rice T . Complications of vitreous surgery for diabetic retinopathy. II. Postoperative complications. Ophthalmology. 1983; 90(5):522-30. DOI: 10.1016/s0161-6420(83)34540-1. View

11.

Simunovic M, Maberley D . ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR PROLIFERATIVE DIABETIC RETINOPATHY: A Systematic Review and Meta-Analysis. Retina. 2015; 35(10):1931-42. DOI: 10.1097/IAE.0000000000000723. View

12.

Han X, Guo C, Li Y, Hui Y . Effects of bevacizumab on the neovascular membrane of proliferative diabetic retinopathy: reduction of endothelial cells and expressions of VEGF and HIF-1α. Mol Vis. 2012; 18:1-9. PMC: 3253067. View

13.

Klein B . Overview of epidemiologic studies of diabetic retinopathy. Ophthalmic Epidemiol. 2007; 14(4):179-83. DOI: 10.1080/09286580701396720. View

14.

Williams D, Burke J, Williams G . Clearance of experimental vitreous hemorrhage after panretinal cryotherapy is related to macrophage influx. Arch Ophthalmol. 1990; 108(4):595-7. DOI: 10.1001/archopht.1990.01070060143065. View

15.

da R Lucena D, Ribeiro J, Costa R, Barbosa J, Scott I, de Figueiredo-Pontes L . Intraoperative bleeding during vitrectomy for diabetic tractional retinal detachment with versus without preoperative intravitreal bevacizumab (IBeTra study). Br J Ophthalmol. 2009; 93(5):688-91. DOI: 10.1136/bjo.2008.151233. View

16.

Smith J, Steel D . Anti-vascular endothelial growth factor for prevention of postoperative vitreous cavity haemorrhage after vitrectomy for proliferative diabetic retinopathy. Cochrane Database Syst Rev. 2015; (8):CD008214. PMC: 6599827. DOI: 10.1002/14651858.CD008214.pub3. View

17.

Li T, Hu J, Du S, Chen Y, Wang S, Wu Q . ERK1/2/COX-2/PGE2 signaling pathway mediates GPR91-dependent VEGF release in streptozotocin-induced diabetes. Mol Vis. 2014; 20:1109-21. PMC: 4119234. View

18.

Hernandez-Da Mota S, Nunez-Solorio S . Experience with intravitreal bevacizumab as a preoperative adjunct in 23-G vitrectomy for advanced proliferative diabetic retinopathy. Eur J Ophthalmol. 2010; 20(6):1047-52. DOI: 10.1177/112067211002000604. View

19.

di Lauro R, De Ruggiero P, di Lauro R, di Lauro M, Romano M . Intravitreal bevacizumab for surgical treatment of severe proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 2010; 248(6):785-91. DOI: 10.1007/s00417-010-1303-3. View

20.

Yang C, Yeh P, Yang C . Intravitreal long-acting gas in the prevention of early postoperative vitreous hemorrhage in diabetic vitrectomy. Ophthalmology. 2007; 114(4):710-5. DOI: 10.1016/j.ophtha.2006.07.047. View